Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 06/05/2024 at 17:50, 5 months 15 days ago

Newron Pharmaceuticals to Host 2024 Investor Day in New York City

Investor Day New York City Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/05/2024 at 17:45, 5 months 15 days ago

Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
Newron Pharmaceuticals announces 2024 Investor Day in New York City focusing on evenamide for treatment-resistant schizophrenia. Leading experts to present new findings

Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide Neurobiology
BRIEF

published on 05/13/2024 at 07:05, 6 months 8 days ago

Newron Pharmaceuticals Announces Positive Results for Evenamide in Schizophrenia Study

Clinical Study Schizophrenia Newron Pharmaceuticals Evenamide Mental Health Treatment
BRIEF

published on 05/13/2024 at 07:05, 6 months 8 days ago

Newron Pharmaceuticals annonce des résultats positifs pour l'Evenamide dans une étude sur la schizophrénie

Schizophrénie Étude Clinique Produits Pharmaceutiques Newron Evenamide Traitement De Santé Mentale
PRESS RELEASE

published on 05/13/2024 at 07:00, 6 months 8 days ago

Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Newron Pharmaceuticals S.p.A. presents compelling additional data from study 008A showcasing the efficacy of evenamide in poorly responding schizophrenia patients. Significant multi-domain benefits observed in PANSS and CGI-C ratings

Clinical Trial Study Results Newron Pharmaceuticals Evenamide Schizophrenia Patients
BRIEF

published on 04/30/2024 at 07:05, 6 months 21 days ago

Newron annonce le succès de son étude sur la schizophrénie Evenamide

Evenamide Résistant Aux Traitements Traitement De La Schizophrénie Étude De Phase II/III Inhibition Glutamatergique
BRIEF

published on 04/30/2024 at 07:05, 6 months 21 days ago

Newron Reports Success in Evenamide Schizophrenia Study

Evenamide Schizophrenia Treatment Treatment-resistant Phase II/III Study Glutamatergic Inhibition
PRESS RELEASE

published on 04/30/2024 at 07:00, 6 months 21 days ago

Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Newron Pharmaceuticals S.p.A. announces positive Phase II/III study results of evenamide in schizophrenia patients, meeting primary and key secondary endpoints with good tolerability

Schizophrenia Newron Pharmaceuticals Evenamide Phase II/III Study Glutamatergic Inhibition
BRIEF

published on 04/08/2024 at 07:05, 7 months 13 days ago

Newron Pharmaceuticals partage des données prometteuses lors du congrès SIRS 2024

Essais Cliniques Schizophrénie Produits Pharmaceutiques Newron Evenamide Résistant Aux Traitements
BRIEF

published on 04/08/2024 at 07:05, 7 months 13 days ago

Newron Pharmaceuticals Shares Promising Data at 2024 SIRS Congress

Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide Treatment-resistant

Accesswire

Published on 11/21/2024 at 12:00, 58 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 58 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 28 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 55 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 58 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 23 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 43 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 51 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 58 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 28 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 50 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 38 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE